You just read:

Antidote for Rapid Reversal of Pradaxa® (dabigatran etexilate) Progresses Into Next Stage of Clinical Investigation with Study in Canadian Patients

News provided by

Boehringer Ingelheim (Canada) Ltd.

Sep 22, 2014, 08:00 ET